Blogopmaak
DCRT's latest article on the development of tailored splice switching oligonucleotides for progressive brain disorders in Europe
This article that we wrote with our colleagues from Tuebingen describes the state of the art in ASO treatment options for rare neurological diseases. Both 1 Mutation 1 Medicine (1M1M) and Dutch Center for RNA Therapeutics (DCRT) aim to develop patient-specific ASOs and treat eligible patients within Europe and the Netherlands, respectively. The article offers insight into the challenges and advantages of this type of treatment and describes regulatory issues, patient eligibility criteria, safety studies, ASO development, envisioned treatment and measuring clinical outcomes. It gives a very clear overview of what DCRT and 1M1M have done to prepare for treatment of eligible patients.
posted on January 23, 2023
Master student Tracy Wüsthoff joins the DCRT for an internship
Come and join the DCRT at the Dutch Antisense Therapeutics Symposium in Groningen!
Master student Okke Faber joins the DCRT
DCRT's Ype Elgersma will be interviewed on television about his work on epilepsy
Happy Christmas holidays from all of us at DCRT!
Guest researchers at the DCRT
Join us on 12 and 13 June 2025 in Groningen, The Netherlands, for the 4th Dutch Antisense Therapeutics Symposium
DCRT interview in the newsletter of Centre for Future Affordable Sustainable Therapy Development (FAST)
DCRT travel grant recipients, Edwin van Oosten and Raúl Andrés about the OTS meeting
First DCRT newsletter